AIM
KYNB

Alambic Investment Management’s Kyntra Bio KYNB Stock Holding History

Alambic Investment Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-444
Closed -$597K – 476
2017
Q3 		$597K Sell
444
-460
-51% -$485K 0.07% 328
2017
Q2 		$730K Sell
904
-116
-11% -$80.8K 0.09% 318
2017
Q1 		$629K Sell
1,020
-12
-1% -$7.31K 0.08% 360
2016
Q4 		$552K Buy
1,032
+288
+39% +$144K 0.1% 308
2016
Q3 		$385K Buy
+744
New +$350K 0.09% 332

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alambic Investment Management's KYNB Position: Q4 2017 in Review

Alambic Investment Management sold out of Kyntra Bio (KYNB) in Q4 2017, closing a stake of 444 shares — an estimated $597K sold.

Alambic Investment Management first reported a position in KYNB in Q3 2016 and held it in 5 quarters. The position peaked at $730K in Q2 2017. 187 funds tracked by Wall St. Rank hold KYNB as of Q4 2017.

  • Alambic Investment Management reported no remaining Kyntra Bio position as of Q4 2017 after selling out during the quarter.
  • Alambic Investment Management sold 444 Kyntra Bio shares in Q4 2017, an estimated $597K.
  • Alambic Investment Management first reported a position in Kyntra Bio in Q3 2016 and held it in 5 quarters.
  • Alambic Investment Management's Kyntra Bio position peaked at $730K in Q2 2017.
  • 187 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2017.

Based on Alambic Investment Management's 13F filing for Q4 2017, filed 2 Feb 2018.